Authors
Latest:
P Values and 'Data Dredging' in Clinical ResearchWe spoke with Dr. Garrett-Mayer about concerns regarding statistical probability (P) values and “data dredging” in clinical research.
Latest:
The Role of Rucaparib in Ovarian CancerWe spoke with Dr. Elizabeth Swisher about the ARIEL2 trial and the role of rucaparib in ovarian cancer.
Latest:
New Biomarker May Help Detect Metastatic Endometrial CancerWe spoke with Dr. G. Larry Maxwell, Chair of the Department of Obstetrics and Gynecology at Inova Fairfax Hospital, about a potential new biomarker to help distinguish metastatic versus nonmetastatic disease in endometrial cancer.
Latest:
Applying Biologic Advances in Multiple Myeloma to Clinical PracticeIn this video, Gareth J. Morgan, MD, discusses the new biologic advances in multiple myeloma and how they are currently being applied to clinical practice.
Latest:
First Human Study Taking Place With Fatty Acid Synthase InhibitorWe spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.
Latest:
Researchers Discuss MLL-Rearranged Acute Myeloid LeukemiasIn this interview, researchers discuss their analysis of a specific type of acute myeloid leukemia.
Latest:
The Role of Checkpoint Inhibitors in Advanced Lung CancerDr. Heather Wakelee discusses the management of lung cancer patients who have early or delayed progression while being treated with an immune checkpoint inhibitor.
Latest:
Lung Cancer Immunotherapy Updates From ASCOIn this podcast interview, Dr. Hossein Borghaei discusses some of the latest science presented at ASCO that focuses on immunotherapy in lung cancer.
Latest:
Immunotherapy Activity Shown in Multiple Myeloma TrialIn this interview, Dr. Ivan Borrello talks about a new approach to treating multiple myeloma at the American Society of Hematology Annual Meeting, held December 3–6, 2016.
Latest:
Potassium Channel Blockers Show Promise as Treatment for Brain TumorsHighly druggable ion channels, which are common therapeutic targets for heart disease and neurological conditions, may represent useful targets in cancer treatment as well, according to researchers from the University of California at San Francisco.
Latest:
Mutations May Help Identify Laryngeal Tumors with Favorable PrognosisResearchers have identified mutations that may help distinguish which laryngeal cancer patients could benefit from therapy, since the disease is notoriously resistant to chemotherapeutic treatments.
Latest:
PD-L1 As a Predictive Biomarker for Anti-PD-1/Anti-PD-L1 Therapies in Non-Small Cell Lung CancerImmunotherapies, such as anti-PD-1 and anti-PD-L1 antibodies, offer promising new treatment options for various malignancies including non-small cell lung cancer (NSCLC). With the advent of these immunotherapies, much interest and energy has been focused on developing a companion predictive biomarker.
Latest:
Pivotal PD-1 Treatment Helps Change Standard of Care in Lung Cancer“Having the opportunity to work within the industry in that sort of capacity, and then seeing a drug translate into clinical benefit in the clinic, was very exciting and gratifying.”
Latest:
ASCO 2015: Sarcoma Poster Presentations & DiscussionsSarcomas are a heterogeneous and motley collection of cancers, which struggle with an identity crisis on many levels. The trials often lump vastly different subgroups, and are often unable to collect sufficient numbers of any one disease subtype to complete a unique cohort.
Latest:
Treating Skin-Associated Toxicities Related to EGFR InhibitorsIn my practice, I am constantly being asked how to properly treat scalp involvement in relation to these skin toxicities.
Latest:
Genetic Susceptibility to Leukemia in PediatricsAs part of our coverage of the ASH Annual Meeting held December 3rd to 6th in San Diego, today we are speaking with Kim Nichols, MD, director of the Cancer Predisposition Division at St. Jude Children's Research Hospital. At this year’s meeting, Dr. Nichols will be participating in a session on genetic susceptibility to leukemia.
Latest:
Nanoparticle-Based Treatment in MelanomaPenn State College of Medicine researchers have discovered a new class of drugs that may keep a deadly form of skin cancer from becoming resistant to treatment.
Latest:
Chlorambucil/Rituximab Combination Delayed Progression in MALT LymphomaPatients with mucosa-associated lymphoid tissue (MALT) lymphoma had improved event-free survival when treated with chlorambucil plus rituximab compared with either therapy alone.
Latest:
Link Between Fanconi Anemia Genetic Mutations and Cancer RiskResearchers have discovered that genetic mutations associated with Fanconi Anemia may also result in a higher risk for certain cancers, even in patients who don't exhibit symptoms of the disease.
Latest:
New Potential Therapy to Prevent ChemobrainAs healthcare providers caring for oncology patients, we are all too familiar with the physical effects of chemotherapy, including chemobrain. A University of Kansas researcher may have identified a possible therapy to prevent this side effect.
Latest:
Understanding the Genomic Landscape of Colorectal TumorsWe spoke with Dr. Luis Diaz about his recent presentation on immunotherapy in colorectal cancer at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.
Latest:
Lenalidomide Maintenance Prolongs PFS in Elderly DLBCLFor the first time, a study shows that using an immunomodulatory agent as maintenance therapy prolongs progression-free survival for patients with diffuse large B-cell lymphoma after first-line treatment with rituximab plus CHOP.
Latest:
Obinutuzumab Plus Chemotherapy Lengthens PFS in Follicular LymphomaObinutuzumab-based therapy is superior to rituximab-based therapy in patients with previously untreated advanced follicular lymphoma.
Latest:
The Multifaceted Experience of Multigene Panel Testing for Breast CancerIn this interview with Mary Daly, MD, PhD, she gives an overview of multigene panel testing for breast cancer, and how they can be used by clinicians to interpret risk and treat accordingly.
Latest:
Study Reveals Treatment Strategy for Triple-Negative Breast CancerMateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.
Latest:
Identifying Circulating Exosomes as a Biomarker in GliomaIn this video, Michael Ciesielski, PhD, of Roswell Park Cancer Institute in Buffalo, talks about circulating exosomes isolated from the serum of malignant glioma patients enrolled in a completed phase I clinical trial of an anti-survivin vaccine (SurVaxM).
Latest:
Study Reveals Mechanism of Antileukemic Effects of Early Childhood VaccinationA new study by an international team led by researchers at the University of California, San Francisco (UCSF), has shed light on the mechanism of action for the anticancer effects of the Haemophilus influenzae Type b (Hib) vaccine, specifically against acute lymphoblastic leukemia (ALL).
Latest:
Metastatic Kidney Cancer: An 'Embarrassment of Riches' For Clear Cell HistologyWhile seven drugs have been approved for clear cell renal cell carcinoma (ccRCC) since 2005, the most appropriate systemic therapy for non-clear cell renal cell carcinoma (nccRCC) is unknown.
Latest:
XRCC2 Gene May Contribute to Testicular Cancer Treatment ResistanceScientists from The Institute of Cancer Research in London identified a gene which may contribute to testicular cancer treatment resistance.
